Biologics for Moderate to Severe Asthma in Children From the department of Paediatrics at Masaka Regional Referral Hospital, UGANDA: A case series

Biologic therapies play a significant role in reducing exacerbations, hospitalizations and the need for maintenance systemic steroids, while also improving the quality of life in patients with severe asthma. The evidence for their clinical efficacy comes from randomised controlled trials (RCTs), extension studies, metanalyses and real-world data.Biologics offer significant benefits for managing severe asthma, particularly for individuals with type 2 inflammation, by reducing exacerbations, improving lung function, and enhancing quality of life, according to the ERS. These medications target specific inflammatory pathways involved in asthma, leading to improved control and reduced reliance on oral corticosteroids.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-06-30
DOI
https://doi.org/10.5281/zenodo.17480857
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biologics for Moderate to Severe Asthma in Children From the department of Paediatrics at Masaka Regional Referral Hospital, UGANDA: A case series

Zenodo (CERN European Organization for Nuclear Research)
Asthma and respiratory diseases
article

Biologics for Moderate to Severe Asthma in Children From the department of Paediatrics at Masaka Regional Referral Hospital, UGANDA: A case series

article en

Abstract

Biologic therapies play a significant role in reducing exacerbations, hospitalizations and the need for maintenance systemic steroids, while also improving the quality of life in patients with severe asthma. The evidence for their clinical efficacy comes from randomised controlled trials (RCTs), extension studies, metanalyses and real-world data.Biologics offer significant benefits for managing severe asthma, particularly for individuals with type 2 inflammation, by reducing exacerbations, improving lung function, and enhancing quality of life, according to the ERS. These medications target specific inflammatory pathways involved in asthma, leading to improved control and reduced reliance on oral corticosteroids.

Zenodo (CERN European Organization for Nuclear Research)
Masaka Hospital (UG), Ministry of Agriculture, Animal Industry and Fisheries (UG), Institute of Child Health (IN)
Openalex Percentile: Top 40%
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Biologics for Moderate to Severe Asthma in Children From the department of Paediatrics at Masaka Regional Referral Hospital, UGANDA: A case series · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS